Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial

INTELLANCE‐J was a phase 1/2 study of a potent antibody‐drug conjugate targeting epidermal growth factor receptor (EGFR), depatuxizumab mafodotin (Depatux‐M), as a second‐ or first‐line therapy, alone or combined with chemotherapy or chemoradiotherapy in 53 Japanese patients with World Health Organi...

Descripción completa

Detalles Bibliográficos
Autores principales: Narita, Yoshitaka, Muragaki, Yoshihiro, Kagawa, Naoki, Asai, Katsunori, Nagane, Motoo, Matsuda, Masahide, Ueki, Keisuke, Kuroda, Junichiro, Date, Isao, Kobayashi, Hiroyuki, Kumabe, Toshihiro, Beppu, Takaaki, Kanamori, Masayuki, Kasai, Shota, Nishimura, Yasuko, Xiong, Hao, Ocampo, Christopher, Yamada, Masakazu, Mishima, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645742/
https://www.ncbi.nlm.nih.gov/pubmed/34609773
http://dx.doi.org/10.1111/cas.15153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645742/
https://www.ncbi.nlm.nih.gov/pubmed/34609773
http://dx.doi.org/10.1111/cas.15153

Ejemplares similares